Brief: Can-Fite Submits IND Application To FDA To Conduct Phase IIb Clinical Trial Of Namodenoson In MASH Patients
03/04/2024 12:02
April 3 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN FITE BIOPHARMA LTD - NAMODENOSON DEMONSTRATED
ANTI-FIBROSIS,
ANTI-STEATOSIS AND ANTI-INFLAMMATORY EFFECTS IN FORMER PHASE IIA
STUDY
* CAN-FITE: SUBMITS FDA WITH AN IND APPLICATION TO CONDUCT
PHASE
IIB CLINICAL TRIAL OF NAMODENOSON IN MASH PATIENTS
* CAN FITE BIOPHARMA LTD - PATIENT ENROLMENT FOR PHASE IIB
STUDY
IS ONGOING IN EUROPE AND ISRAEL
Source text for Eikon: ID:nBwc1nZRHa
Further company coverage: CANF.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage